Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditure of $2,693,312 ...

Terumo Blood and Cell Technologies has entered into a memorandum of understanding (MOU) with South Korea’s KBIOHealth to jointly develop workforce training initiatives aimed at enhancing cell ...

The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditures of $2,693,312 ...

Aged individuals and astronauts experience bone loss despite rigorous physical activity. Bone mechanoresponse is in-part ...

Scientists have unveiled a revolutionary method for mass-producing high-quality human mitochondria, potentially transforming ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell ...

The following is a summary of "Controversial Role Of Cd151 In Different Solid Tumors: Promoter Or Suppressor?,” published in ...

A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...